Versican Plus DP lyophilisate and solvent for suspension for injection for dogs

Authorised

- Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
- Canine distemper virus, strain CDV Bio 11/A, Live

Product identification

Medicine name:
VERSICAN PLUS DP ΛΥΟΦΙΛΟΠΟΙΗΜΕΝΟ ΥΛΙΚΟ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ
Versican Plus DP lyophilisate and solvent for suspension for injection for dogs

Active substance:
Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
Canine distemper virus, strain CDV Bio 11/A, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
19952.00 50% tissue culture infectious dose / 1.00 Dose

Canine distemper virus, strain CDV Bio 11/A, Live
1258.00 50% tissue culture infectious dose / 1.00 Dose

Pharmaceutical form:
Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AD03

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Greece

Available in:
Greece

Package description:
(ID2) 50 Dose; 50 millilitre(s): Box (plastics) with 50 Vial (glass) each with 1 Dose and 50 Vial (glass) each with 1 millilitre(s)
(ID1) 25 Dose; 25 millilitre(s): Box (plastics) with 25 Vial (glass) each with 1 Dose and 25 Vial (glass) each with 1 millilitre(s)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Hellas S.A.

Marketing authorisation date:
15/09/2016

Manufacturing sites for batch release:
Bioveta a.s.

Responsible authority:
National Organization For Medicines

Authorisation number:
73695/03-08-2021/K-0214901

Date of authorisation status change:
2/08/2021

Reference member state:
Germany

Procedure number:
DE/V/0266/001

Concerned member states:
Belgium Bulgaria Cyprus Greece Hungary Italy Lithuania Luxembourg Netherlands Poland Portugal Romania Spain

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

2613562-paren-20251101.pdf